← Eichor
Study identifier: NCT03144648 Synced from ClinicalTrials.gov · July 30, 2026
● Recruiting

PRECAMA: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women

Condition: Breast Cancer Female  ·  Sponsor: International Agency for Research on Cancer

PhaseN/A
Planned participants3000
Who can joinFemale, 20 Years to 45 Years
Healthy volunteersYes

About this study

Breast cancer has become a major public health problem in Latin America, as it is the most common form of cancer among women. Women are more likely to develop breast cancer at younger age, and to be diagnosed at an advanced stage compared to western women. Over the past twenty years, the mortality from breast cancer in Latin America has also been increasing very rapidly, and is currently the leading cause of cancer mortality. Little is known on specific risk factors for premenopausal breast cancer in general, and in Latin America in particular. There is a lack of specific knowledge on tumor molecular and pathological characteristics of breast cancer in Latin America premenopausal women, and this has major consequences on cancer treatment and survival. To improve our understanding on determinants of breast cancer incidence and mortality in young Latin America women and support preventive actions, we implemented an international, population-based multi-center study in Latin America: the PRECAMA study (Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women (PRECAMA): a multicenter population-based case-control study). PRECAMA is coordinated by the International Agency for Research on Cancer (IARC), and is conducted within 4 Latin American countries: Mexico, Costa Rica, Colombia and Chile. Major aims of the project are the following: 1. To develop a multi-centric population-based case-control study on breast cancer in premenopausal women in several countries…

This description comes directly from the study's public registry record.

Talk to the study team

Sabina Rinaldi, PhD  ·  +33 472738485  ·  rinaldis@iarc.who.int

Always discuss trial participation with your own doctor first.

Locations (13)

Barretos Cancer HospitalBarretos, BrazilCompleted
INCSantiago, Independencia, ChileActive Not Recruiting
Hso-CrscoSantiago, Peñalolén, ChileActive Not Recruiting
FALPSantiago, Providencia, ChileActive Not Recruiting
Grupo Infección y Cáncer. Universidad de AntioquiaMedellín, Antioquia, ColombiaRecruiting
International Hospital of ColombiaBucaramanga, Bucaramanga, ColombiaRecruiting
Facultad de Medicina, Universidad del NorteBarranquilla, ColombiaCompleted
Hospital Internacional de Colombia Fundacion Cardiovascular de ColombiaBucaramanga, ColombiaRecruiting
SENOSAMA foundationBucaramanga, ColombiaRecruiting
Instituto de Oncología HematoOncologosCali, ColombiaCompleted
Public Health University of NarinoPasto, ColombiaRecruiting
Agencia Costarricense de Investigaciones Biomédicas (ACIB)San José, Provincia de San José, Costa RicaCompleted

+ 1 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03144648